"I believe our eventual, greatest successes will come from mutually beneficial associations and partnerships formed with other companies and institutions. In-licensing and out-licensing opportunities can be rewarding to both parties, creating advances in medicine and technology through relationships with outside scientists and business development executives in academia and corporate R & D."

Darrell Brookstein - Executive VP, Business Development & Finance

Keyhole limpet hemocyanin (KLH) is a highly potent T-cell dependent immunostimulatory protein and adjuvant. The molecule has an extensive history of safe and effective use in humans for vaccine development and immunological research. As an essential carrier protein for the rapidly developing field of synthetic conjugate vaccines, KLH has proven to be superior at conferring antigenicity to a wide variety of molecular conjugates and has enabled a broad array of new vaccines and active immunotherapies.

The potent immunogenicity and excellent safety record of KLH also makes it an excellent choice for immunological research applications.